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Note 
 
Incorporating Cost into the Return of Incidental 
Findings Calculus: Defining a Responsible 
Default for Genetics and Genomics Researchers 
 
Emily Scholtes* 
Sandy Cohen lost both her mother and grandmother to 
breast cancer.1 Fearing that she would also become a victim of 
breast cancer, Sandy underwent genetic testing.2 The testing 
revealed that Sandy had a BRCA1 mutation.3 Approximately 
fifty-five to sixty-five percent of women who inherit a BRCA1 
mutation will develop breast cancer sometime during their 
lives.4 Genetics and genomics research led to the discovery of 
the BRCA1 gene mutation.5 Because of this discovery, women 
like Sandy Cohen6 are now empowered to take life-saving pre-
cautions to prevent the development of breast cancer.  
 
*  J.D. Candidate 2016, University of Minnesota Law School; B.A. 2013, 
University of Northern Iowa. Thank you to Professor Susan Wolf for her in-
valuable feedback and guidance. Additional thanks to Sam Bolstad, Jonathan 
Grant, and Joey Dobson for their comments and to the editors and staff of the 
Minnesota Law Review for their tireless efforts. Finally, I must thank my fam-
ily and friends for their unending support, patience, and love. Preparation of 
this Note was supported in part by National Institutes of Health (NIH), Na-
tional Cancer Institute (NCI) and National Human Genome Research Insti-
tute (NHGRI) Grant #1-R01-CA154517 (Gloria Petersen, Barbara Koenig, Su-
san M. Wolf, Principal Investigators) and aided by research conducted for that 
project under the supervision of Professor Wolf. All views expressed are those 
of the author and not necessarily the views of NIH, NCI, or NHGRI. Copyright 
© 2016 by Emily Scholtes. 
 1. Basser Research Ctr. for BRCA, Patient Stories, PENN MEDICINE 
ABRAMSON CANCER CTR., https://cancer.pennmedicine.org/about/patient 
-stories/brca-sandy (last visited Nov. 30, 2015). 
 2. Id.  
 3. Id.  
 4. BRCA1 and BRCA2: Cancer Risk and Genetic Testing Fact Sheet, 
NAT’L CANCER INST., http://www.cancer.gov/about-cancer/causes-prevention/ 
genetics/brca-fact-sheet (last visited Nov. 30, 2015).  
 5. See David Botstein & Neil Risch, Discovering Genotypes Underlying 
Human Phenotypes: Past Successes for Mendelian Disease, Future Approaches 
for Complex Disease, 33 NATURE GENETICS 228, 229 (2003).  
 6. See Angelina Jolie, Opinion, My Medical Choice, N.Y. TIMES (May 14, 
2013), http://www.nytimes.com/2013/05/14/opinion/my-medical-choice.html. 
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Now, imagine that Sandy Cohen did not receive genetic 
testing, but rather enrolled as a participant in a genomics re-
search study. The researchers are studying colon cancer. When 
the researchers sequence Sandy’s genome, they stumble upon 
the BRCA1 gene mutation. They were not looking for the 
BRCA1 gene mutation and this mutation is not related to the 
study. Do the researchers have an ethical or legal duty to offer 
these results to Sandy? This example illustrates the “vigorous 
debate”7 over researchers’ duty to return individual research 
results and incidental findings to research participants. An in-
cidental finding, also known as a secondary finding, is “a find-
ing concerning an individual research participant that has po-
tential health or reproductive importance and is discovered in 
the course of conducting research but is beyond the aims of the 
study.”8 The debate over returning incidental findings has been 
a hot topic in medical and legal circles for many years9 and is 
described as “one of the thorniest current challenges.”10 Cur-
rently, no federal or state laws regulate the disclosure of these 
findings.11 Although many agree that ethical duties arise in re-
turning certain individual results and incidental findings,12 the 
legal implications are much more opaque.13 This legal ambigui-
 
 7. Laura M. Beskow & Wylie Burke, Offering Individual Genetic Re-
search Results: Context Matters, 2 SCI. TRANSLATIONAL MED. 1, 1 (2010).  
 8. Susan M. Wolf et al., Managing Incidental Findings in Human Sub-
jects Research: Analysis and Recommendations, 36 J.L. MED. & ETHICS 219, 
219 (2008) [hereinafter Wolf et al., Managing Incidental Findings]. An inci-
dental finding is not the same as an individual research result. Simply stated, 
if the researcher was looking for the finding, then the finding is an individual 
research result; if not, then the finding is an incidental finding. Erik Parens et 
al., Incidental Findings in the Era of Whole Genome Sequencing?, 43 
HASTINGS CTR. REP. 16, 18 (2013).  
 9. See Marianna J. Bledsoe et al., Return of Research Results from Ge-
nomic Biobanks: Cost Matters, 15 GENETICS MED. 103, 103 (2013). 
 10. Gina Kolata, Genes Now Tell Doctors Secrets They Can’t Utter, N.Y. 
TIMES (Aug. 25, 2012), http://www.nytimes.com/2012/08/26/health/research/ 
with-rise-of-gene-sequencing-ethical-puzzles.html (quoting Francis Collins, 
Director of the National Institutes of Health).  
 11. See Amy L. McGuire et al., Can I Be Sued for That? Liability Risk and 
the Disclosure of Clinically Significant Genetic Research Findings, 24 GENOME 
RES. 719, 719 (2014) (“Yet, no United States regulations directly address this 
issue, and there is no clear case law to rely on.”); Susan M. Wolf, The Role of 
Law in the Debate over Return of Research Results and Incidental Findings: 
The Challenge of Developing Law for Translational Science, 13 MINN. J.L. SCI. 
& TECH. 435, 436 (2012) [hereinafter Wolf, Role of Law] (“There is no law di-
rectly on point.”).  
 12. See Elizabeth R. Pike et al., Finding Fault? Exploring Legal Duties To 
Return Incidental Findings in Genomic Research, 102 GEO. L.J. 795, 809 
(2014). 
 13. See Wolf, Role of Law, supra note 11, at 437.  
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ty raises concerns as ethical recommendations for researchers 
evolve and seem to establish a standard of care for the research 
enterprise.14 An established standard of care may lead to legal 
liability for researchers.15  
Researchers may bear the additional costs that the threats 
of liability and legal ambiguity impose.16 Numerous questions 
arise.17 What results should be disclosed to participants? Who 
should disclose the results? Who should pay for the results? 
How long does a potential duty last? What are the potential 
costs if researchers do not return incidental findings? The cost 
and resource implications of a duty to return incidental find-
ings may severely inhibit the advancement of genetics and ge-
nomics research and threaten the societal benefit of continued 
research.18 Furthermore, as researchers continue to identify 
new genetic and genomic variants, researchers will discover 
more incidental findings and the costs of returning these re-
sults will likely increase.19 Therefore, an informed analysis of 
the medical, legal, and economic implications is needed now to 
ensure appropriate standards are created.  
Compounding this issue are funding concerns that jeopard-
ize future research efforts and life-saving discoveries.20 These 
 
 14. See Ellen Wright Clayton & Amy L. McGuire, The Legal Risks of Re-
turning Results of Genomics Research, 14 GENETICS MED. 473, 473 (2012). 
 15. Id.  
 16. See Susanne B. Haga & Jennifer Q. Zhao, Stakeholder Views on Re-
turning Research Results, in 84 ADVANCES IN GENETICS 42, 68–69 (Theodore 
Friedmann et al. eds., 2013). 
 17. See, e.g., KAREN H. ROTHENBERG & LYNN WEIN BUSH, THE DRAMA OF 
DNA: NARRATIVE GENOMICS 3 (2014) (“Controversial issues abound—such as 
determining whether, what, to whom, when and how genomic information 
should be disclosed to individuals . . . .”); Clayton & McGuire, supra note 14.  
 18. See Gail P. Jarvik et al., Return of Genomic Results to Research Partic-
ipants: The Floor, the Ceiling, and the Choices in Between, 94 AM. J. HUM. GE-
NETICS 818, 820 (2014); Michael R. Ulrich, Resource Restraints: Rethinking 
Disclosure of Individual Genomic Findings, 17 MICH. ST. U. J. MED. & L. 127, 
145 (2012) (“With all of the good that has come from conducting research and 
all the potential discoveries that lie in wait in genomic research it is vital that 
a suitable obligation to return individual results be clarified.”).  
 19. See Bledsoe et al., supra note 9, at 104.  
 20. Sam Stein, House GOP Votes Down NIH Funding Measure One Day 
After Members Praised NIH Funding, HUFFINGTON POST (Mar. 19, 2015), 
http://www.huffingtonpost.com/2015/03/19/nih-funding-_n_6901932.html; Liz 
Szabo, NIH Director: Budget Cuts Put U.S. Science at Risk, USA TODAY (Apr. 
23, 2014), http://www.usatoday.com/story/news/nation/2014/04/23/nih-budget 
-cuts/8056113; Francis Collins Warns of ‘Devastating’ Effect of Budget Crisis 
on NIH-Funded Research, GENOMEWEB (Oct. 7, 2015), https://www 
.genomeweb.com/research-funding/francis-collins-warns-devastating-effect 
-budget-crisis-nih-funded-research. 
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funding shortages have the immediate effect of denying innova-
tive research projects. The National Institutes of Health (NIH) 
was once able to fund one in three research proposals, but in 
the past ten years, this funding ratio has dropped to one in 
six.21 NIH’s budget has lost twenty-five percent of its purchas-
ing power over the last decade due to inflation.22 Limited fund-
ing also presents long-term problems of current researchers 
leaving the field and fewer researchers coming into the field.23 
Studies have shown that scientists are considering moving 
from the United States to other countries to do research.24 
Many commentators are concerned that continued shortages in 
research funding will have lasting negative repercussions for 
genetic and genomic research.25 
Several articles have focused on the ethical and legal is-
sues surrounding the problem of incidental findings in genetics 
and genomics research.26 This Note analyzes the cost implica-
tions of a duty to return incidental findings and how these cost 
implications should shape future policy recommendations for 
genetics and genomics research. This Note takes previous rec-
ommendations one step further to provide an ethically, legally, 
 
 21. Szabo, supra note 20; see also MacKenzie Elmer, Federal Budget Woes 
Slow Medical Research, DES MOINES REG. (Sept. 29, 2014), http://www 
.desmoinesregister.com/story/news/education/2014/09/29/federal-budget-woes 
-slow-medical-research/16411759. 
 22. Szabo, supra note 20; see also Editorial, Elizabeth Warren Plan Would 
Bolster NIH Funding, BOS. GLOBE (Mar. 6, 2015), http://www.bostonglobe 
.com/opinion/editorials/2015/03/05/elizabeth-warren-plan-would-bolster-nih 
-funding/rlFDSwUz5zhNjXklIPCPWN/story.html.  
 23. Szabo, supra note 20; see also John LaMattina, The NIH Needs More 
Funding—Here’s a Proposal That Can Help, FORBES (Mar. 5, 2015), http:// 
www.forbes.com/sites/johnlamattina/2015/03/05/the-nih-needs-more-funding 
-heres-a-proposal-that-can-help; Claire Pomeroy & Eric. R. Kandel, Opinion, 
Cutting Budgets for Medical Research Is Dangerous, CNN (June 6, 2014), 
http://www.cnn.com/2014/06/06/opinion/pomeroy-kandel-medical-research. 
 24. Szabo, supra note 20.  
 25. See, e.g., id.; Pomeroy & Kandel, supra note 23.  
 26. See L. Black et al., Funding Considerations for the Disclosure of Genet-
ic Incidental Findings in Biobank Research, 84 CLINICAL GENETICS 397, 397 
(2013) (“Much of the detail about how [incidental findings] should be handled 
comes from scientific and ethics literature.”). See generally Stephanie A. 
Alessi, The Return of Results in Genetic Testing: Who Owes What to Whom, 
When, and Why?, 64 HASTINGS L.J. 1697 (2013) (addressing the ethical foun-
dations for a duty to return incidental findings and the potential sources of 
legal duties); Richard L. Furman, Jr., Genetic Test Results and the Duty To 
Disclose: Can Medical Researchers Control Liability?, 23 SEATTLE U. L. REV. 
391 (1999) (analyzing potential legal liability to researchers under claims in 
tort, contract, and property law); Pike et al., supra note 12 (proposing that re-
searchers’ potential legal liability should be addressed through the informed 
consent process).  
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and fiscally responsible default rule to apply when researchers 
are not sure whether offering to return results is appropriate. 
This Note proposes that researchers should default to offering 
to return incidental findings in genomics or genetics research to 
participants, unless the researchers weigh the costs and bene-
fits of returning versus the costs and benefits of not returning 
and reasonably conclude that they should not return the inci-
dental findings. The default rule places a minimal burden on 
researchers and also provides guidance and a sense of security 
from the threat of future legal liability. Part I of this Note dis-
cusses the history of medical research liability and the debate 
over the issue of returning research results and incidental find-
ings. Part II analyzes the cost implications of current recom-
mendations for researchers faced with incidental findings in 
genetics and genomics research. Part III argues that policy-
makers need to take cost implications into account, proposes 
some potential recommendations that would address these cost 
considerations, and defines a default rule that will provide 
guidance without overly burdening the genetics and genomics 
research enterprise.  
I.  MEDICAL RESEARCHER LIABILITY AND THE DEBATE 
OVER RETURN OF RESEARCH RESULTS AND 
INCIDENTAL FINDINGS   
Medical research has a long history in the United States.27 
Beginning in the 1960s, research institutions started to develop 
guidelines to ensure the protection of human subjects in re-
search.28 Section A will briefly discuss the history of medical re-
search and researcher liability. Section B will present the de-
bate in genetics and genomics research over whether 
researchers should offer results to participants. Finally, Section 
C will introduce some of the cost implications of returning re-
search results to participants.  
A. HISTORY OF MEDICAL RESEARCH AND RESEARCHER  
LIABILITY  
The goal of medical research is to “pursue generalizable 
 
 27. For a general overview of the medical and research history in the 
United States, visit History of Medicine, NAT’L INSTITS. HEALTH, http:// 
www.nlm.nih.gov/hmd (last updated Oct. 21, 2015).  
 28. Amy L. Davis & Elisa A. Hurley, Setting the Stage: The Past and Pre-
sent of Human Subjects Research Regulations, in BASIC BIOETHICS: HUMAN 
SUBJECTS RESEARCH REGULATION: PERSPECTIVES ON THE FUTURE 9, 9–11 (I. 
Glenn Cohen & Holly Fernandez Lynch eds., 2014).  
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knowledge that will benefit society.”29 On its face, medical re-
search does not explicitly create a duty between the researcher 
and the participant.30 Unlike physician-patient relationships, 
researcher-participant relationships are not considered fiduci-
ary relationships, which is a relationship held in trust.31 Thus, 
researchers are not required to act “primarily for the benefit of 
the individual research subject.”32  
The rights and wellbeing of research participants, however, 
are not inconsequential. The “Common Rule”33 and FDA regula-
tions govern human subjects research.34 The “Common Rule,” 
also known as the Federal Policy for the Protection of Human 
Subjects, applies to nearly all federally-funded human subjects 
research.35 As a part of obtaining “legally effective informed 
consent of the subject,”36 the Common Rule requires that re-
searchers disclose reasonably foreseeable risks and benefits to 
 
 29. Ulrich, supra note 18, at 128.  
 30. This lack of a duty is in stark contrast to physicians who are “regard-
ed as fiduciaries of their patients and as such are expected to act in their pa-
tients’ best interests.” Roger L. Jansson, Researcher Liability for Negligence in 
Human Subject Research: Informed Consent and Researcher Malpractice Ac-
tions, 78 WASH. L. REV. 229, 242 (2003) (footnotes omitted).  
 31. See Franklin G. Miller et al., Incidental Findings in Human Subjects 
Research: What Do Investigators Owe Research Participants?, 36 J.L. MED. & 
ETHICS 271, 273 (2008) (“Unlike the physician, the investigator has not under-
taken to act in the subject’s best interests when entering into the relationship; 
she has not taken on a fiduciary role.”). 
 32. McGuire et al., supra note 11, at 721; see also Wolf, Role of Law, supra 
note 11, at 443 (“Both law and ethics have conceived of the research and clini-
cal spheres as generally quite distinct.”).  
 33. 45 C.F.R. § 46 (2014). In September 2015, the Department of Health 
and Human Services announced proposed revisions to the Common Rule. See 
Human Subjects Research Protections: Enhancing Protections for Research 
Subjects and Reducing Burden, Delay, and Ambiguity for Investigators, 80 
Fed. Reg. 53,931, 53,936 (proposed Sept. 8, 2015), https://www.federalregister 
.gov/articles/2015/09/08/2015-21756/federal-policy-for-the-protection-of 
-human-subjects. The proposed rule revision seeks to make the informed con-
sent process more meaningful. Id. 
 34. 21 C.F.R. §§ 50, 56 (2015). These regulations apply to research involv-
ing experimental drugs, biological products, and medical devices subject to 
FDA approval. Id. Similar to the Common Rule, the FDA regulations require 
informed consent and IRB review and approval. Id. §§ 50.20–50.27; id. 
§§ 56.103, 56.109, 56.111. Unlike the Common Rule, the FDA regulations pro-
vide fewer exceptions to the informed consent requirements and fewer waiv-
ers. Compare 45 C.F.R. § 46.116(c)–(d) (2014) (delineating the Common Rule’s 
requirements for modifying or waiving consent), with 21 C.F.R. § 50.23 (2015) 
(listing FDA regulations’ exceptions from general consent requirements).  
 35. See Federal Policy for the Protection of Human Subjects (“Common 
Rule”), U.S. DEP’T HEALTH & HUMAN SERVS., http://www.hhs.gov/ohrp/ 
humansubjects/commonrule/index.html (last visited Nov. 30, 2015).  
 36. 45 C.F.R. § 46.116. 
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participants.37 The Common Rule also directs researchers to 
minimize potential risks to participants and ensure that the 
risks are reasonable in relation to the anticipated benefits.38 
The Common Rule, however, does not create an express cause 
of action for participants who allege a violation.39  
Although the Common Rule does not enable participants to 
sue researchers, research participants may be able to recover 
against researchers under a negligence regime.40 While law-
suits against researchers have been historically rare, research-
related litigation has been increasing.41 Several cases illustrate 
the recent shift in courts’ treatment of researcher-participant 
relationships and how these relationships may give rise to du-
ties never before anticipated.  
In Grimes v. Kennedy Krieger Institute,42 the Maryland 
Court of Appeals held that “the very nature of nontherapeutic 
research on human subjects can, and normally will, create spe-
cial relationships out of which duties arise.”43 Grimes involved 
research on lead-paint abatement in houses rented to families 
with young children.44 The researchers found that the plaintiffs’ 
children had elevated levels of lead in their blood.45 Plaintiffs 
brought suit arguing that the researchers failed to warn them 
of the hazardous levels of lead paint.46 Vacating the lower 
court’s decision,47 the court of appeals found that the research-
ers had a duty given the researchers’ ability to “anticipate, dis-
cover, and understand the potential risks to the health of their 
subjects.”48  
A few years before Grimes, the United States District 
Court for the Northern District of Illinois found in Blaz v. Mi-
chael Reese Hospital that a physician leading a research pro-
gram had a duty to warn a patient, whom the physician had 
 
 37. Id.  
 38. Id. § 46.111.  
 39. See Susan M. Wolf et al., The Law of Incidental Findings in Human 
Subjects Research: Establishing Researchers’ Duties, 36 J.L. MED. & ETHICS 
361, 368 (2008) [hereinafter Wolf et al., Law of Incidental Findings]. 
 40. See Jansson, supra note 30, at 236.  
 41. See Michelle M. Mello et al., The Rise of Litigation in Human Subjects 
Research, 139 ANNALS INTERNAL MED. 40, 40 (2003). 
 42. 782 A.2d 807 (Md. 2001).  
 43. Id. at 834–35.  
 44. Id. at 819.  
 45. Id. at 825.  
 46. Id. at 825–26. 
 47. Id. at 858.  
 48. Id. at 851.  
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never treated, of the risks of previous treatment received.49 In 
Blaz, the plaintiff participated in a research study performed 
by the defendant, a physician who had never treated the plain-
tiff.50 The study analyzed the connection between x-ray treat-
ments, which the plaintiff had undergone as a child, and the 
prevalence of tumors.51 Almost 20 years after the study, the 
plaintiff developed neural tumors and sued the physician for 
failure to warn him of the study’s finding that he might be at 
an increased risk for developing tumors.52 Even though the de-
fendant did not have a physician-patient relationship with the 
plaintiff, the district court found that the defendant owed a du-
ty to the plaintiff because of the reasonable foreseeability of 
harm, the negligible burden on the defendant to warn, the de-
fendant’s “special position to acquire the information”53 and the 
plaintiff “was in no position to find out”54 the information. Like 
Grimes, the court in Blaz also found that the defendant’s posi-
tion as the head of the research program created a “special re-
lationship” required “for a finding of duty in the absence of a 
physician-patient relationship.”55 
Some commentators argue that cases like Grimes and Blaz 
represent a larger trend of increased liability exposure for med-
ical researchers and that these cases could lead to more law-
suits in the future.56 While the legal duty of researchers re-
mains unclear and scarcely addressed in courts, the issue of 
returning research results and incidental findings presents 
some interesting challenges that the court will likely have to 
face someday in the near future.  
B. DEBATE OVER RETURN OF RESEARCH RESULTS AND  
INCIDENTAL FINDINGS 
The use of genetics and genomics for nontherapeutic re-
search57 raises challenging ethical and legal issues for re-
 
 49. 74 F. Supp. 2d 803, 805 (N.D. Ill. 1999).  
 50. Id. at 804.  
 51. Id.  
 52. Id. 
 53. Id. at 805–06.  
 54. Id.  
 55. Id. at 806–07.  
 56. See, e.g., Jansson, supra note 30, at 230 (“This period of increased le-
gal and public scrutiny of the research enterprise will likely lead to a dramatic 
rise in lawsuits by human subjects.”).  
 57. It is important to note a distinction between therapeutic research, 
which has a possibility for immediate benefit to the research participants, and 
nontherapeutic research, which does not offer immediate clinical benefits to 
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searchers. During the course of genetics and genomics research, 
researchers are likely to discover incidental findings. While in-
cidental findings can arise in any area of medical research,58 
genetics and genomics research raises particular concerns be-
cause of the likelihood and scope of potential incidental find-
ings.59 Some of these findings have clear clinical significance,60 
whereas other incidental findings have no clear significance.61  
Currently, researchers and others in the field are reaching 
a general consensus that certain ethical obligations62 require 
the return of incidental findings in some circumstances.63 It is 
important to note that the ethical duty to return incidental 
findings is distinct from the issue of legal obligations to return 
incidental findings.64 Potential legal liability and the sources for 
liability for failure to return incidental findings remains a point 
of contention.65 Neither the Common Rule nor the FDA regula-
tions directly address incidental findings.66 Although no court 
 
the participants. See Matthew P. Gordon, A Legal Duty To Disclose Individual 
Research Findings to Research Subjects?, 64 FOOD & DRUG L.J. 225, 227 
(2009). 
 58. See, e.g., id. at 224–26 (discussing incidental findings in MRI research 
and CT colonography).  
 59. Pike et al., supra note 12, at 800.  
 60. See, e.g., Naomi H. Brodersen et al., Anticipated Reactions to Genetic 
Testing for Hereditary Non-Polyposis Colorectal Cancer Susceptibility, 66 
CLINICAL GENETICS 437, 437 (2004) (explaining that hereditary non-polyposis 
colorectal cancer disorder “has been shown to be caused by mutations of DNA 
mismatch repair genes”).  
 61. See, e.g., Catherine Gliwa & Benjamin E. Berkman, Do Researchers 
Have an Obligation To Actively Look for Genetic Incidental Findings?, 13 AM. 
J. BIOETHICS 32, 36 (2013) (“Genomic science is still in its infancy, and the 
amount we know about the relationship between genomic data and human 
disease is dwarfed by the amount we do not yet know.”).  
 62. See Ulrich, supra note 18, at 136–43 (grounding an ethical obligation 
to return incidental findings in respect for the participants, beneficence, reci-
procity, and other ethical principles). But see Leslie A. Meltzer, Undesirable 
Implications of Disclosing Individual Genetic Results to Research Participants, 
6 AM. J. BIOETHICS 28, 28 (2006) (“[T]heir justification for disclosure rests on 
the mistaken view that principles of beneficence, respect, reciprocity, and/or 
justice ethically require researchers to offer participants individual genetic 
results.”).  
 63. See Clayton & McGuire, supra note 14 (“There is substantial consen-
sus that people should be offered results that could trigger interventions that 
are lifesaving or that could avert serious adverse health outcomes . . . .”).  
 64. Wolf, Role of Law, supra note 11, at 440–41.  
 65. See Pike et al., supra note 12, at 830; Wolf et al., Law of Incidental 
Findings, supra note 39, at 362 (discussing the uncertainty of whether and 
when a researcher may be liable for failing to return incidental findings).  
 66. For a discussion of how several provisions of the federal regulations 
governing human subjects research are relevant to the disclosing and manag-
ing of incidental findings, see Wolf et al., Law of Incidental Findings, supra 
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has directly addressed the issue of a researcher’s legal duty to 
disclose incidental findings, increased researcher liability 
claims and recent court cases create fear of legal liability for 
genetics and genomics researchers. 
While Grimes and Blaz suggest that researchers have some 
sort of a special duty to their participants, only one case argua-
bly addresses the issue of whether a researcher has a duty to 
disclose individual research findings. In Ande v. Rock, the 
plaintiffs sued researchers for failing to inform them that their 
child had cystic fibrosis.67 The plaintiffs had their first child in 
1993 and at that time, the plaintiffs received a pamphlet de-
scribing the cystic fibrosis research.68 The plaintiffs’ child was 
placed in the “blinded control” group, which meant that alt-
hough the plaintiffs’ child tested positive for factors indicative 
of cystic fibrosis, the researchers did not inform the plaintiffs.69 
Two years later, the child was diagnosed with cystic fibrosis 
and the plaintiffs had already conceived a second child, who 
was also diagnosed with cystic fibrosis.70 The court ultimately 
dismissed the plaintiffs’ medical malpractice and negligence 
claims.71 For the medical malpractice claim, the court found 
that no physician-patient relationship existed between the 
plaintiffs and any of the defendants, so the medical malpractice 
claim could not prevail.72 On the claim of negligence, the lower 
court found that the claim was time-barred and plaintiffs did 
not appeal the ruling.73  
Although the court never reached the issue of the re-
searchers’ duty to return individual research results to the 
plaintiffs, some legal scholars argue that Ande is still informa-
tive.74 Ande may reflect courts’ resistance to requiring re-
searchers to disclose individual research results.75 The lack of 
litigation regarding return of research results and incidental 
findings, however, has failed to calm fears of legal liability in 
the research community.76  
 
note 39, at 366–68.  
 67. 647 N.W.2d 265, 268 (Wis. Ct. App. 2002). 
 68. Id. at 269.  
 69. Id.  
 70. Id. at 270.  
 71. Id. at 276; id. at 268 (“The circuit court dismissed all of the state 
claims, except those for medical malpractice.”).  
 72. Id. at 272.  
 73. Id. at 269.  
 74. See, e.g., Gordon, supra note 57, at 234.  
 75. See id.  
 76. See Wolf, Role of Law, supra note 11, at 437 (“It appears to be little 
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In addition to the previous litigation involving researchers 
and courts expanding the duties of researchers, ethical obliga-
tions may create unintended consequences that burden the re-
search enterprise and put researchers in the firing line for neg-
ligence lawsuits.77 Several articles have addressed the fear that 
ethic recommendations will be misconstrued as legal obliga-
tions.78 As researchers adopt these ethical recommendations, 
these new practices may give rise to a corresponding legal 
standard of care for researchers.79 Two scholars, Ellen Wright 
Clayton and Amy McGuire, stated “One thing is certain—if 
these practices become routine, they will be legally required. 
This is the way tort law has worked for decades.”80 
Besides the concerns of ethical obligations morphing into 
legal obligations, the current ethical recommendations provide 
inconclusive guidance for researchers, leading to inconsistent 
practice.81 Although many commentators and researchers agree 
that “[incidental findings] should be returned only when they 
are analytically valid, have significant health implications, and 
are clinically actionable,”82 these criteria fail to provide all the 
answers.83 Inconsistent practice arguably can lead to legal lia-
 
reassurance that no court . . . has yet found anyone liable for mishandling re-
turn of results or incidental findings in the context of human subjects re-
search.”).  
 77. See, e.g., W. Nicholson Price II, Legal Implications of an Ethical Duty 
To Search for Genetic Incidental Findings, 13 AM. J. BIOETHICS 48, 48 (2013) 
(explaining that ethical obligations may create a standard of care and “provide 
grounds for a negligence lawsuit”).  
 78. See, e.g., Wolf, Role of Law, supra note 11, at 438 (“Though law and 
ethics are sometimes confused, they are distinct.”).  
 79. See Clayton & McGuire, supra note 14, at 475 (discussing how ethical 
obligations may become evidence of standard of care for researchers); Pike et 
al., supra note 12, at 815 (“[A]s this emerging ethical obligation increasingly 
becomes standard or customary practice in research, the emerging ethical ob-
ligation could give rise to a legal obligation to return [incidental findings], the 
failure of which could result in legal liability.”); Price, supra note 77, (“[I]f an 
ethical duty to search for incidental genetic findings arises and becomes wide-
spread at some point in the future, it may become the legal standard of 
care . . . .”). 
 80. Clayton & McGuire, supra note 14, at 475. 
 81. See Pike et al., supra note 12, at 808–09.  
 82. Id. at 809.  
 83. See Gordon, supra note 57, at 253 (“[T]he determination whether a 
particular individual research finding has clinical utility may often be far from 
simple . . . . In addition, the investigators may not be adequately trained to 
assess clinical utility.”); Robert Klitzman, Questions, Complexities, and Limi-
tations in Disclosing Individual Genetic Results, 6 AM. J. BIOETHICS 34, 35 
(2006) (“[D]efinitional questions will arise about results that are neither clear-
ly ‘analytically valid’ nor invalid, but of indeterminate validity. Results may 
range significantly in the precise degree to which they identify a characteris-
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bility for both ends of the spectrum—the return of incidental 
findings or the failure to return incidental findings.84  
Requiring researchers to return incidental findings to par-
ticipants also raises serious concerns about therapeutic miscon-
ception.85 Although a consistent definition has not been estab-
lished,86 therapeutic misconception occurs “when a research 
subject fails to appreciate the distinction between the impera-
tives of clinical research and of ordinary treatment, and there-
fore inaccurately attributes therapeutic intent to research pro-
cedures.”87 In the case of genetics and genomics research, 
returning certain incidental findings, especially those with am-
biguous or unknown significance, arguably causes “unnecessary 
scares” and violates the ethical obligation to minimize harm to 
research participants.88 The risk for therapeutic misconception 
makes the need for legal clarity especially important for genet-
ics and genomics researchers.89 More research is needed to see 
whether and to what extent return of results creates a thera-
peutic misconception, but the concern should be considered 
when addressing the ethical and legal obligations of genetic 
and genomic researchers.90  
 
tic—that is, their predictive value.”). 
 84. See Pike et al., supra note 12, at 812–13 (“This gap between the 
emerging majority view that some [incidental findings] ought to be returned 
and the reality that [incidental findings] often are not returned . . . has led to 
growing concern about potential legal liability . . . . [T]here is a growing sense 
that we may be standing at the precipice of legal liability . . . .”); cf. Gary E. 
Marchant & Rachel A. Lindor, Personalized Medicine and Genetic Malpractice, 
15 GENETICS MED. 921, 921 (2013) (“[W]hen a new technology such as genetic 
testing is taken up . . . unevenly, a gap develops between the care provided by 
early adopters versus that by late adopters, again providing an opening for li-
ability based on the disparity in treatment, with both early adopters and late 
adopters facing potential risk for being too quick or not quick enough to adopt 
the new technology.”).  
 85. See Clayton & McGuire, supra note 14, at 474.  
 86. See Gail E. Henderson et al., Clinical Trials and Medical Care: Defin-
ing the Therapeutic Misconception, 4 PLOS MED. 1735, 1735 (2007).  
 87. Charles W. Lidz & Paul S. Appelbaum, The Therapeutic Misconcep-
tion: Problems and Solutions, 40 MED. CARE 55, 57 (2002).  
 88. Ellen W. Clayton & Lainie F. Ross, Letter to the Editor, Implications 
of Disclosing Individual Results of Clinical Research, 295 J. AM. MED. ASS’N 
37, 37 (2006).  
 89. See Alessi, supra note 26, at 1712–13 (“[A]n individual subject might 
misinterpret the goal of the research and where the project’s priorities lie—
that is, in the population rather than the individual. The potential for misun-
derstanding makes it imperative that any legal duty to report results be nar-
rowly drawn so as not to place a burden on researchers that will only under-
mine the research it aims to promote.”).  
 90. See Clayton & McGuire, supra note 14, at 474 (explaining that the is-
sue of therapeutic misconception “deserves further study”).  
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C. RETURN OF INCIDENTAL FINDINGS AND COST  
CONSIDERATIONS 
The ethical and legal ambiguity surrounding return of in-
cidental findings raises several cost concerns for genetics and 
genomics researchers.91 Numerous commentators have ex-
pressed anxiety that a legal duty to return incidental findings 
or individual research results will overly burden the research 
enterprise and threaten the ultimate purpose of medical re-
search.92 The potential cost implications of a duty to return in-
cidental findings to research participants can be significant and 
requires more consideration.93  
One significant cost of returning incidental findings is the 
cost of assuring that the results are analytically valid, clinically 
valid, and actionable. It is clear that disclosing incidental find-
ings imposes costs on the research enterprise.94 Prior to disclos-
ing incidental findings to participants, researchers must verify 
and evaluate the findings to prevent disclosure of mistaken or 
misleading data, which would harm the participant by causing 
undue anxiety and unnecessary testing.95 The costs—including 
time, money, and resources—of determining the validity and 
significance of the results, confirming these results, and provid-
ing adequate follow up and counseling can be extremely bur-
 
 91. See generally Conrad V. Fernandez et al., Considerations and Costs of 
Disclosing Study Findings to Research Participants, 170 CAN. MED. ASS’N J. 
1417, 1417 (2004) (discussing the costs of disclosure as three broad categories: 
risk associated with the procedures, consequences of disclosure, and logistics 
of the study); Kathryn A. Phillips et al., Is the “$1000 Genome” Really $1000? 
Understanding the Full Benefits and Costs of Genomic Sequencing, 23 TECH. & 
HEALTH CARE 373 (2015).  
 92. See Miller et al., supra note 31, at 278 (“As a general principle, the 
scope of the responsibility for incidental findings should be assessed in light of 
the potential impact on the primary mission of research, which is to promote 
socially valuable, generalizable knowledge.”); Pilar N. Ossorio, Letting the 
Gene Out of the Bottle: A Comment on Returning Individual Research Results 
to Participants, 6 AM. J. BIOETHICS 24, 25 (2006) (“If offering individual re-
sults becomes the norm, I fear that we will sacrifice a tremendous amount of 
research . . . .”); cf. Bledsoe et al., supra note 9, at 104 (arguing that in the con-
text of biobanks, “the costs and burdens to the research enterprise more broad-
ly could be enormous and one cost to society could be inhibiting important re-
search”). 
 93. See Parens et al., supra note 8 (“Our approaches have to take into ac-
count the real costs associated with generating and reporting such information 
. . . .”); Wolf et al., Law of Incidental Findings, supra note 39, at 364–65 
(“Striking the right balance between necessary management of [incidental 
findings] and containment of research costs will be important.”).   
 94. See Pike et al., supra note 12, at 802.  
 95. See Wolf et al., Law of Incidental Findings, supra note 39, at 376.  
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densome on the research enterprise.96  
Disclosing incidental findings may also impose significant 
costs by requiring researchers to obtain meaningful informed 
consent. Researchers are required to obtain informed consent 
from research participants.97 If researchers are required to re-
turn or at least offer to return incidental findings, this could 
drastically change the process of receiving informed consent. 
Researchers will likely struggle to provide participants enough 
information to allow participants to give meaningful informed 
consent.98 Some commentators fear that the cost of acquiring 
consent and returning incidental findings could “hobble . . . crit-
ical areas of research.”99 Obtaining informed consent could pre-
sent a significant cost100 for researchers who face a duty to re-
turn incidental findings and these costs should be considered 
when determining researchers’ duties to participants.  
Besides the cost of obtaining informed consent, the act of 
returning the incidental results is difficult and costly.101 Genet-
ics and genomics information is difficult to explain to partici-
pants and this task becomes even more difficult when the im-
plications of genetic information are unknown or unclear.102 
Sometimes, the researchers are not the most qualified to share 
the incidental findings because they may lack the skill and 
knowledge to convey the results in a meaningful and under-
 
 96. See Pilar Ossorio, Taking Aims Seriously: Repository Research and 
Limits on the Duty To Return Individual Research Findings, 14 GENETICS 
MED. 461, 464 (2012) (“The burdens and costs of returning individual IFs and 
RRs—including money, people’s time, and the opportunity cost of not doing 
more research because one is engaged in returning information to contribu-
tors—aggregate swiftly.”). See generally Ulrich, supra note 18, at 132 (discuss-
ing the minimum requirements for returning results to participants).  
 97. 45 C.F.R. § 46.116 (2014). The National Human Genome Research In-
stitute defines “informed consent” as “[a] voluntary agreement to participate 
in human subjects research . . . based on adequate knowledge and understand-
ing.” Informed Consent for Genomics Research: Glossary, NAT’L HUM. GENOME 
RES. INST., https://www.genome.gov/27559022 (last visited Nov. 30, 2015). 
 98. See Beskow & Burke, supra note 7 (“[I]t is difficult to imagine how 
participants could be given enough information to make a fully informed deci-
sion . . . .”).  
 99. Clayton & McGuire, supra note 14, at 475.  
 100. See, e.g., id. (explaining that the Centers for Disease Control and Pre-
vention decided to forego genetic research as the “cost of obtaining adequate 
consent was estimated to be in the millions of dollars”). 
 101. See Bledsoe et al., supra note 9 (“Delivering genetic information is 
costly and complex.”).  
 102. See Clayton & McGuire, supra note 14, at 476 (“Helping people under-
stand complex, probabilistic information is hard enough; it becomes much 
more difficult when that information is new and its clinical impact is not 
clear.”).  
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standable way to the participant.103 Researchers may need help 
returning incidental findings and this may impose more costs 
on researchers by requiring them to hire additional staff or 
spend more time explaining these results.  
As stated above, researchers facing an ethical obligation to 
return incidental findings may face future legal liability if that 
ethical obligation morphs into a legal obligation. Legal obliga-
tions will undoubtedly lead to increased costs for researchers.104 
Arguably, once a standard of care is established, the standard 
is likely to persist.105 Furthermore, researchers may be moti-
vated to continue to return incidental findings, as a form of “de-
fensive research,” analogous to the practice of defensive medi-
cine by physicians.106 The mere threat of liability may drive 
researchers’ behavior and impose additional burdens on the re-
search enterprise.107 
While many commentators discuss the costs that research-
ers may face when returning incidental findings, some com-
mentators also discuss the potential implications for the health 
care system. Clayton and McGuire referred to this as the 
“largely unspoken concern.”108 Drawing a parallel to the clinical 
context, Clayton and McGuire argue that returning incidental 
findings may increase health care costs, both for the individual 
and society at large, because these findings will potentially lead 
to downstream tests and side effects.109 Clayton and McGuire 
provide a helpful example of variants in HFE, the gene associ-
ated with hemochromatosis.110 Arguably, these results of vari-
ants should not be shared when uncovered in research because 
population-based screening for the same variants was rejected 
as not cost effective because the variants were poorly pene-
 
 103. See Sharon F. Terry, The Tension Between Policy and Practice in Re-
turning Research Results and Incidental Findings in Genomic Biobank Re-
search, 13 MINN. J.L. SCI. & TECH. 691, 721–22 (2012).  
 104. See Ulrich, supra note 18, at 134 (arguing that “potential downstream 
cost of researcher liability could evolve from creating an ethical duty”).  
 105. See Price, supra note 77 (explaining that once a legal duty is estab-
lished, the duty will continue in the long term “because the legal standard of 
care is generally a one-way ratchet to which requirements may be added but 
only rarely removed”). 
 106. Id. at 49.  
 107. See Wolf et al., Law of Incidental Findings, supra note 39, at 366 (em-
phasizing that the “fear of legal liability should not drive the evolution of du-
ties”). 
 108. Clayton & McGuire, supra note 14, at 475.  
 109. Id.; see also Terry, supra note 103, at 721.  
 110. Clayton & McGuire, supra note 14, at 475. 
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trant.111  
While returning results imposes costs, not returning re-
sults can also be costly. Most literature fails to address this as-
pect of cost to return, but the tangible and intangible costs of 
not returning incidental findings to participants can be detri-
mental to society as well as the research enterprise. First, not 
returning incidental findings can be harmful to society through 
increased demands on the health care system. If a researcher 
returns an incidental finding to a participant, this individual 
may be able to take preventative steps to avoid future health 
care costs. Thus, by not returning their findings, researchers 
may deprive participants of the opportunity to take these steps 
and avoid increased health care costs in the future.112 Second, 
not returning results can lead to intangible costs that are diffi-
cult to quantify, but could threaten the public perception of ge-
nomics and genetics research. Society’s loss of trust and the 
perceived lack of reciprocity113 could lead individuals to forego 
participating in genomics and genetics research. Although the-
se costs are difficult to calculate, these negative implications 
should also be considered when determining whether incidental 
findings should be offered to participants.  
Given the extent and scope of these potential costs,114 plus 
recent budget concerns, the legal ambiguity surrounding re-
searchers’ duty to return incidental findings to participants 
presents compounding problems for researchers.115 The goal of 
 
 111. Id.  
 112. The cost-effectiveness of preventative care raises its own debates and 
criticisms that go beyond the scope of this Note. See generally Joshua T. Cohen 
et al., Does Preventative Care Save Money? Health Economics and the Presi-
dential Candidates, 358 NEW ENG. J. MED. 661, 661 (2008) (“Studies have con-
cluded that preventing illness can in some cases save money but in other cases 
can add to health care costs.”). 
 113. See Jennifer Viberg et al., Incidental Findings: The Time Is Not Yet 
Ripe for a Policy for Biobanks, 22 EUR. J. HUM. GENETICS 437, 438 (2014) 
(“[Reciprocity] holds that people deserve something in return for their contri-
bution . . . . It may also be argued that research would benefit from disclosing 
individual research results to participants; because offering something in re-
turn might motivate participation . . . [and] could be useful in recruiting and 
retaining research participants.” (citations omitted)).  
 114. Calculating these costs presents a significant hurdle that further re-
search will need to address. See Terry, supra note 103, at 720 (“In a climate of 
evolving technology, data aggregation, and societal interest in genetic infor-
mation, it is difficult to determine the weight of benefits and risks.”); Susan M. 
Wolf, Letter to the Editor, Return of Results in Genomic Biobank Research: 
Ethics Matters, 15 GENETICS MED. 157, 158 (2013) (“Quantifying the cost of 
handling [individual research results] and [incidental findings] will not be 
easy.”).  
 115. See, e.g., Beskow & Burke, supra note 7, at 4 (“In some contexts, the 
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medical research is to benefit society as a whole, rather than 
the individual participants, so the costs imposed on the re-
search enterprise should be included in the calculus to deter-
mine and clarify the ethical and legal obligations of researchers 
to return incidental findings. 
II.  ANALYZING POTENTIAL COSTS OF RETURNING 
INCIDENTAL FINDINGS   
A duty to disclose incidental findings, whether ethical or 
legal, is costly. Returning those findings is costly. The reality is 
that medical researchers are faced with tradeoffs. Researchers 
have limited funding and scarce resources. These scarce re-
sources need to be allocated efficiently in order to advance the 
goal of medical research, which is the pursuit of generalizable 
knowledge that benefits society as a whole. Returning inci-
dental findings has the ultimate effect of diverting money, 
time, and researchers away from actual research. This Note 
does not argue that incidental findings should never be re-
turned to participants, but it does strive to point out the need 
for research, discussion, and consideration of the cost implica-
tions of returning incidental findings in genetics and genomics 
research. Section A addresses what incidental findings should 
be offered to participants. Section B discusses who should offer 
to return the results. Section C analyzes who should pay to re-
turn incidental findings, while Section D looks at how long a 
potential duty to return findings could last. Finally, Section E 
summarizes the potential costs of not returning incidental find-
ings to research participants.  
A. WHAT SHOULD BE RETURNED? 
A good starting point for this analysis is looking at what 
findings should be returned, which is not an easy question to 
answer. The question encompasses several other issues, includ-
ing informed consent, verification of the results, the scope of 
the results that should be returned, and the scope of a re-
searcher’s duty to search for incidental findings buried in their 
results. This Note will address each of these issues in turn.  
The most recent recommendations for returning incidental 
findings were published in 2014 by the Clinical Sequencing Ex-
 
rationale for providing individual results is insufficient to justify spending 
scarce research resources to do so.”); Klitzman, supra note 83 (“[R]esearch re-
sources are already limited, given budgetary constraints at the National Insti-
tutes of Health . . . yet the costs of testing and counseling can be very high.”).  
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ploratory Research (CSER) Consortium and the Electronic 
Medical Records and Genomics (eMERGE) Network working 
group.116 The working group delineated a floor and a ceiling for 
returning research results.117 The working group also set forth 
five guiding principles and discussed remaining areas of con-
troversy.118 Using these recommendations as a starting point, 
this Section will address remaining questions related to obtain-
ing informed consent, verifying the validity of results, deter-
mining the scope of results that should be returned, and ad-
dressing the duty to search.  
1. Informed Consent  
The issue of what to return to research participants starts 
with consent. In other words, what has the participant said 
about his or her desire to receive potential incidental findings. 
The Common Rule requires that researchers obtain “legally ef-
fective informed consent” from the research participant.119 The 
need for informed consent and what constitutes informed con-
sent has generated considerable debate, some of which goes be-
yond the scope of this Note, in the genetics and genomics re-
search community.  
Consent is very much relevant to the potential costs im-
posed on researchers.120 For genetics or genomics research, ge-
netic counselors are needed to provide the necessary infor-
mation to allow participants to give adequate informed 
consent.121 The role of genetic counseling is to help people un-
derstand the medical and psychological implications of genetic 
and genomic contributions to disease.122 Because of their short 
 
 116. Jarvik et al., supra note 18. 
 117. Id. at 821 (defining the floor “as the return of well-established, im-
portant actionable genetic findings relevant to the intent of the research study 
or uncovered in the course of usual research procedures” and the ceiling “as 
the entire genome sequence or some representation of it”).  
 118. Id.  
 119. 45 C.F.R. § 46.116 (2014).  
 120. See Clayton & McGuire, supra note 14, at 475 (providing an example 
of one study in which attaining adequate consent would cost millions of dol-
lars).  
 121. See Ulrich, supra note 18, at 132. But see Paul S. Appelbaum et al., 
Models of Consent to Return of Incidental Findings in Genomic Research 44, 
HASTINGS CTR. REP. 22, 24, 27 (2014) (outlining four different models of con-
sent to return of incidental findings and concluding that “[n]one of the possible 
models for informed consent to return of incidental findings in genomic re-
search is ideal”).  
 122. Barbara Bernhardt, Genetic Counselors and the Future of Clinical Ge-
nomics, 6 GENOME MED. 49, 49 (2014). Helping participants understand po-
tential implications of genomic sequencing is a complicated process that re-
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supply, genetic counselors are usually quite expensive.123 In ad-
dition to genetic counselors, most commentators agree that 
consent forms should address the possibility of incidental find-
ings.124 Besides the ethical and legal justifications for providing 
this information, the cost of reconsent provides additional sup-
port for consent prior to the start of the research study. 
Reconsent is the process of recontacting the participant to re-
ceive their consent for additional use of their information125 or 
the potential return of results that had not been addressed in 
the prior consent process.126 Two recent studies have calculated 
the average cost of reconsent to be approximately $50 per indi-
vidual.127 These costs are likely to vary depending on the meth-
od of reconsent.  
Related to the issues of consent and reconsent, many ethi-
cists argue that a person has a right not to know one’s own 
 
quires tempering participants’ expectations, educating participants about the 
limitations of genomic sequencing and genetic testing, and explaining the un-
certainty of some potential results. Id. at 50. A recent study interviewed twen-
ty-nine genetic counselors and research coordinators about their experiences 
with obtaining informed consent for genomic sequencing, highlighting the 
challenges with participant understanding and managing participant expecta-
tions. Ashley N. Tomlinson et al., “Not Tied up Neatly with a Bow”: Profes-
sionals’ Challenging Cases in Informed Consent for Genomic Sequencing, J. 
GENETIC COUNSELING (forthcoming 2016) (“He had highlighted the consent 
form very carefully and he highlighted the word ‘genome’ and he kept saying 
‘gnome’ . . . he was like ‘What’s a gnome? What does that mean? . . . Is that in 
my body? Can you take it out of me?’”).  
 123. See Klitzman, supra note 83 (“Genetic counselors are already in short 
supply.”); Ulrich, supra note 18, at 133.  
 124. See Wolf et al., Law of Incidental Findings, supra note 39, at 374 (ar-
guing that a process must be in place to review the informed consent plan to 
ensure that potential participants are aware of the possibility of incidental 
findings and whether and when this information will be offered); Wolf et al., 
Managing Incidental Findings, supra note 8, at 228.  
 125. Michele L. Cote et al., Re-contacting Participants for Inclusion in the 
Database of Genotypes and Phenotypes (dbGaP): Findings from Three Case-
Control Studies of Lung Cancer, 6 GENOME MED. 54, 54 (2014).  
 126. See Paul S. Appelbaum et al., Researchers’ Views on Informed Consent 
for Return of Secondary Results in Genomic Research, 17 GENETICS MED. 644, 
645 (2014) (describing a staged consent process in which there is a “brief men-
tion of secondary findings at the time of initial consent but with more detailed 
consent for return of specific findings obtained if and when reportable results 
are found”).  
 127. Cote et al., supra note 125, at 57 (estimating the total cost of re-
consent to be the annual salary of one full-time interviewer, which resulted in 
approximately $47.60 per individual); Evette J. Ludman et al., Glad You 
Asked: Participants’ Opinions of Re-Consent for dbGaP Data Submission, 5 J. 
EMPIRICAL HUM. RES. ETHICS 9, 15 (2010) (finding that cost of seeking re-
consent was approximately $50 per participant).  
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genes or genomic sequence128 and if they do not consent to the 
return of genetic and genomic research results or incidental 
findings, then the researcher should not return anything. In-
deed, one of the working group’s principles states that partici-
pants should have the right to refuse any results that are of-
fered.129 Thus, once a participant has denied consent to the 
return of research results or incidental findings, the researcher 
cannot offer to return any result to the participant.  
2. Verifying the Analytical Validity of the Results  
Another looming issue is whether the results must be veri-
fied in a CLIA-certified lab130 before being returned to the par-
ticipant. As Gail P. Jarvik and her colleagues point out, this is 
still an area of controversy.131 Before offering results to a partic-
ipant, researchers must verify that their findings are analyti-
cally valid132 to prevent false reporting and potential harm to 
participants. Some contend that this requires the results to be 
tested in a CLIA-certified lab.133 Arguably, requiring results to 
be CLIA certified would reduce the likelihood of returning inac-
curate results. Inaccurate results could lead to unnecessary fol-
low-up tests for the participant, increased costs for participants 
and the health care system, and stress on the participant and 
others. Most research labs, however, are not CLIA-certified 
labs.134 Requiring CLIA certification could be costly to research-
ers.135 In some cases, CLIA certification of research results may 
 
 128. For more discussion on the debate over one’s right not to know in the 
research context, see Gert Helgesson, Autonomy, the Right Not To Know, and 
the Right To Know Personal Research Results: What Rights Are There, and 
Who Should Decide About Exceptions?, 42 J.L. MED. & ETHICS 28 (2014).  
 129. Jarvik et al., supra note 18.  
 130. Clinical Laboratory Improvement Amendments (CLIA) is a federal 
statute that dictates the certification and oversight of clinical laboratory test-
ing. Certification of Laboratories, 42 U.S.C. § 263a (2012). A CLIA-certified lab 
is a lab that is in compliance with the CLIA regulations.  
 131. Jarvik et al., supra note 18, at 822.  
 132. Lisa Eckstein et al., A Framework for Analyzing the Ethics of Disclos-
ing Genetic Research Findings, 42 J.L. MED. ETHICS 190, 194 (2014) (“The ac-
curacy of predictions about a genetic variant’s presence or absence in a re-
search participant is at the heart of most definitions of analytic validity.”). 
 133. See, e.g., Vardit Ravitsky & Benjamin S. Wilfond, Disclosing Individ-
ual Genetic Results to Research Participants, 6 AM. J. BIOETHICS 8, 10 (2006).  
 134. Ellen Wright Clayton, Incidental Findings in Genetics Research Using 
Archived DNA, 36 J.L. MED. & ETHICS 286, 290 (2008) (“Most research labora-
tories do not adhere to CLIA requirements . . . .”).  
 135. Black et al., supra note 26, at 403 (arguing that such confirmatory 
testing “will inevitably increase the costs of IF disclosure”); Klitzman, supra 
note 83 (“Repeated tests through Clinical Laboratory Improvement Amend-
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be impossible.136 Some argue that if the results cannot be CLIA 
certified, then participants should be informed of this at the 
time of return and should be recommended to have the results 
verified by a CLIA-certified lab.137  
Even if the results cannot be verified by a CLIA-certified 
lab, researchers still have a responsibility to confirm the ana-
lytical validity of the results.138 Whether researchers verify 
their results through a CLIA-certified lab or by some other 
means,139 researchers must bear some costs to ensure that find-
ings offered to participants are accurate. This cost is unavoida-
ble for researchers, who must prevent harm or undue stress on 
research participants and comply with ethical and legal man-
dates.  
3. Scope of Incidental Findings that Should Be Offered to  
Participants  
Assuming valid informed consent was given and the re-
sults are adequately confirmed, what information should be of-
fered to a participant? At the extremes of the spectrum of inci-
dental findings to offer, researchers could offer to return 
nothing or offer to return everything. While returning nothing 
may seem advantageous because it minimizes the cost and 
burden of interpreting and returning incidental findings, most 
researchers have rejected this approach as being ethically un-
supportable.140  
On the other end of the spectrum is the offer to return eve-
rything. Although some argue that this approach may be very 
beneficial for the research community by affirming the value of 
research participation and building trust in the research enter-
prise,141 this approach is likely to be overly costly and burden-
some on researchers and some results may arguably violate the 
Common Rule by harming participants with the return of re-
 
ments (CLIA)-certified labs can also be expensive.”).  
 136. Jarvik et al., supra note 18, at 823 (explaining that “research circum-
stances might make a CLIA-compliant test impossible”).  
 137. See Wolf et al., Managing Incidental Findings, supra note 8, at 231.  
 138. It is important to note that analytical validity is distinct from clinical 
validity. See id.  
 139. For examples of other means to verify analytical validity, see Eckstein 
et al., supra note 132.  
 140. See Pike et al., supra note 12, at 833.  
 141. See Laura M. Beskow et al., Offering Aggregate Results to Participants 
in Genomic Research: Opportunities and Challenges, 14 GENETICS MED. 490, 
491–92 (2012).  
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sults that have unknown significance.142 Furthermore, this ap-
proach may blur the lines of clinical care and medical research 
and could, thus, contribute to therapeutic misconception.143  
Rather than selecting one of the two extremes, Jarvik and 
colleagues state that “analytically and clinically valid infor-
mation that is of an important and actionable medical nature 
and that is identified as part of the research process should be 
offered to a research participant.”144 Essentially, when re-
searchers have a valid research result for which the participant 
can take preventative measures to protect his or her health, 
then researchers should offer this result to the participant.145 
This general principle breaks down, however, when policymak-
ers try to define “actionable.”146  
The definition of “actionable” varies by research study and 
context.147 One clear example of this is in a research study for 
children. Should the child or the child’s parents be offered re-
sults of adult-onset findings?148 Historically, the answer has 
been no.149 Some commentators argue, however, that these find-
ings are actionable and should be returned.150  
The danger of an ambiguous definition of “actionable” leads 
to liability concerns down the road. If researchers fear that 
they will be sued for not returning an “actionable” result, then 
they may choose to return everything or more than they should. 
As seen above, returning too much information can lead to neg-
ative consequences and impose costs on researchers and partic-
ipants.  
Given the ambiguity of how to define “actionable,” it is dif-
 
 142. Id. at 492–93; Pike et al., supra note 12, at 835.  
 143. Beskow et al., supra note 141, at 493.  
 144. Jarvik et al., supra note 18.  
 145. Id. at 821.  
 146. Id. (“The definition of what is actionable is a matter of judgment.”).  
 147. Richard R. Fabsitz et al., Ethical and Practical Guidelines for Report-
ing Genetic Research Results to Study Participants: Updated Guidelines from a 
National Heart, Lung, and Blood Institute Working Group, 3 CIRCULATION 
CARDIOVASCULAR GENETICS 574, 575–76 (2010) (“Actionable means that dis-
closure has the potential to lead to an improved health outcome . . . . Actiona-
ble may include surveillance and interventions to improve clinical course, such 
as by delaying onset, leading to earlier diagnosis, increasing likelihood of less 
burdensome disease, or expanding treatment options.”).  
 148. Jarvik et al., supra note 18, at 821. 
 149. Id.  
 150. See id.; cf. Robert C. Green, ACMG Recommendations for Reporting of 
Incidental Findings in Clinical Exome and Genome Sequencing, 15 GENETICS 
MED. 565, 568 (2013) (recommending that searching for and returning find-
ings should not be limited by the age of the participant in the clinical setting).  
2016] A RESPONSIBLE DEFAULT 1193 
 
ficult for researchers to predict how many actionable incidental 
findings they may recover. Several studies have looked into the 
likelihood of identifying incidental findings. Lucy-Enid Ding 
and colleagues published a study in 2014 looking at a screening 
panel of 24 conditions.151 They found that approximately 2.7% of 
screened individuals would have an incidental finding.152 Mi-
chael O. Dorschner and colleagues performed a study in 2013 to 
determine the likelihood of identifying actionable findings.153 
Christopher A. Cassa and co-authors found a rate of 6.88% of 
participants having an incidental finding that was recommend-
ed for disclosure.154 But, Yali Xue and colleagues reported 11% 
of 179 screened individuals had an incidental finding.155 These 
studies illustrate the challenge for researchers to predict the 
potential number of actionable incidental findings.156 Without 
being able to reasonably predict the number of actionable inci-
dental findings, researchers will struggle to predict the costs to 
return such results.  
4. Costs Associated with a Potential Duty To Search  
Finally, if researchers have a responsibility to return some 
research results to participants, does this responsibility require 
researchers to search for results buried in one’s genome? Jarvik 
and colleagues recommend that research resources should be 
primarily used for scientific discovery and, thus, researchers do 
not have a duty to search for findings.157 Such a duty is likely to 
be costly and overly burdensome for researchers.158  
 
 151. Lucy-Enid Ding et al., The Impact of Reporting Incidental Findings 
from Exome and Whole-Genome Sequencing: Predicted Frequencies Based on 
Modeling, 17 GENETICS MED. 197, 197 (2015).  
 152. Id. at 198. 
 153. Michael O. Dorschner et al., Actionable, Pathogenic Incidental Find-
ings in 1,000 Participants’ Exomes, 93 AM. J. HUMAN GENETICS 631, 631 
(2013).  
 154. Christopher A. Cassa et al., Disclosing Pathogenic Genetic Variants to 
Research Participants: Quantifying an Emerging Ethical Responsibility, 22 
GENOME RES. 421, 423 (2012).  
 155. Yali Xue et al., Deleterious- and Disease-Allele Prevalence in Healthy 
Individuals: Insights from Current Predictions, Mutation Databases, and Pop-
ulation-Scale Resequencing, 91 AM. J. HUM. GENETICS 1022, 1030 (2012).  
 156. See also Julia Karow, As Labs Start Returning Incidental Findings, 
Weighing Variant Pathogenicity Remains Challenge, GENOME WEB (May 14, 
2014), https://www.genomeweb.com/sequencing/labs-start-returning-incidental 
-findings-weighing-variant-pathogenicity-remains (“The lack of clear criteria 
for classifying variants as pathogenic likely leads to differences in incidental 
findings rates between laboratories . . . .”).  
 157. Jarvik et al., supra note 18.  
 158. See Wolf et al., Law of Incidental Findings, supra note 39, at 376.  
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In 2013, Catherine Gliwa and Benjamin E. Berkman eval-
uated the benefits and costs of a duty to search.159 Gliwa and 
Berkman conclude that researchers have no duty to search, re-
lying in part on the costs that would be imposed on research-
ers.160 Prior to any filtering, researchers would be faced with 
approximately 80,000 variants per exome or 3 to 4 million vari-
ants of each genome for each participant.161 Next, researchers 
would filter these results to leave only those variants that are 
most likely to cause disease.162 Then, researchers must deter-
mine whether a specific variant is likely to cause disease, but 
this is a tedious process that must be done manually.163 Consid-
erable time, resources, and money are needed to perform such 
an analysis.  
In addition, many commentators and policymakers fear 
that an ethical duty to search may evolve into a legal duty.164 
Given the costs and resources required to satisfy a duty to 
search, the threat of legal liability for failure to search could 
have the negative consequence of driving researchers out of do-
ing research as the costs of research may not justify the bene-
fits.  
Issues about what incidental findings to offer to research 
participants and the costs of offering these results are extreme-
ly complex and can have serious legal implications. Issues of in-
formed consent, analytical validation, which results should be 
returned, and potential duties to search illustrate the complexi-
ty of returning incidental findings to participants. These issues 
and how they are resolved have significant consequences for 
both researchers and participants and thus require careful con-
sideration by policymakers and those drafting recommenda-
tions.  
B. WHO SHOULD RETURN?  
Who should return the results is another area that raises 
cost and legality concerns. At first glance it may seem obvious 
to have the researchers return the results. The researchers de-
signed the study. The researchers recruited the participants. 
 
 159. Gliwa & Berkman, supra note 61, at 32.  
 160. Id. at 41.  
 161. Id. at 37; see Leslie G. Biesecker, Opportunities and Challenges for the 
Integration of Massively Parallel Genomic Sequencing into Clinical Practice: 
Lessons from the ClinSeq Project, 14 GENETICS MED. 393, 394 (2012).  
 162. Gliwa & Berkman, supra note 61, at 37.  
 163. Id.  
 164. See Price, supra note 77, at 49.  
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The researchers performed the genetic tests or genomic se-
quencing. The researchers found the incidental finding. In 
Grimes, the court held that researchers have a “special rela-
tionship” with their participants165 and this could be interpreted 
to mean that researchers should be the ones to offer to return 
results to participants. But it is important to remember that 
the researchers discovered an incidental finding, something 
they were not looking for. The researchers may have no 
knowledge of the significance of a particular variant, how to in-
terpret the variant, or what the variant might mean (if any-
thing).166 The method of returning results remains an area of 
contention and in need of further research.167  
One method proposed is that the researcher bears the re-
sponsibility to return incidental findings to participants. Re-
turning genomic or genetic results in an ethical manner re-
quires time and resources. Explaining genomic and genetic test 
results is very complex.168 If the results yield novel findings or 
have unknown significance, returning and explaining these re-
sults becomes exponentially more difficult.169 The danger of mis-
interpretation or miscommunication is significant. The threat 
of misinterpretation may not be enough to justify no return of 
findings, but it highlights the challenge facing researchers who 
have to explain these results to a participant. These challenges 
increase the amount of time, resources, and money that need to 
be diverted from other areas of the research budget.170 In a re-
cent study, researchers determined that to disclose results to 
research participants cost $68 and required 78 minutes on av-
erage.171 These calculations are likely to vary considerably de-
pending on the type of study.172  
If the researcher has the responsibility to return and ex-
plain the incidental findings, the researcher may need to hire 
 
 165. Grimes v. Kennedy Krieger Inst., 782 A.2d 807, 834–35 (Md. 2001).  
 166. See Black et al., supra note 26, at 401 (“Variance on who should dis-
close [incidental findings] persists, and there is no clear overlap or consensus 
in the guidance.”); Jarvik et al., supra note 18 (“[S]ome investigative teams are 
not qualified to interpret and/or return the results.”).  
 167. Jarvik et al., supra note 18, at 823.  
 168. See Clayton & McGuire, supra note 14, at 476.  
 169. Id.  
 170. See Black et al., supra note 26, at 402 (explaining that researchers 
may not have the “required time to prepare for and perform the disclosure”).  
 171. Kurt D. Christensen et al., Disclosing Individual CDKN2A Research 
Results to Melanoma Survivors: Interest, Impact, and Demands on Research-
ers, 20 CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 522, 522 (2011). 
 172. See id. at 527–28.  
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additional personnel to do so.173 Because researchers may not be 
the most qualified to return the results, additional genetic 
counselors or the participant’s clinician may need to be in-
volved in the disclosure. Even if the researcher is qualified to 
return the results, the researcher may not have the time to re-
turn the results. Regardless of the reason, hiring additional 
personnel will increase research costs.  
Some also fear that requiring the researchers to return the 
results will blur the lines between clinical and research and 
could lead to therapeutic misconception.174 Returning results 
can lead participants to believe that researchers will provide 
certain results or all results. Therapeutic misconception can 
lead to negative consequences as participants who expect to re-
ceive certain results, even if they were informed that they 
would not receive such results, may feel betrayed or cheated 
when they do not receive those results.175 This could lead to se-
rious implications for medical research as individuals begin to 
distrust the research enterprise or if participants feel they are 
being mistreated or disrespected. The potential negative stigma 
caused by therapeutic misconception is difficult to quantify into 
tangible costs.  
While no explicit statute or court case imposes legal liabil-
ity on researchers to return results, the potential for future lia-
bility should cause policymakers to consider these possible 
downstream consequences and consider the costs when propos-
ing policy guidelines. Who returns the results is an important 
consideration from an ethical, legal, cost, and efficiency stand-
point.  
C. WHO PAYS? 
Returning incidental findings to research participants can 
be a costly endeavor. Deciding who will bear these costs has 
important implications. Some argue that these costs should be 
included in the research budget.176 While this may seem like an 
 
 173. See id. at 528.  
 174. See Alessi, supra note 26, at 1712; cf. supra notes 85–90 and accompa-
nying text.  
 175. See Alessi, supra note 26, at 1711–12.  
 176. See, e.g., Fernandez et al., supra note 91, at 1419 (“Researchers and 
granting agencies should consider the offer to return results to research par-
ticipants as a mandatory part of practice and adjust budgets and duration of 
funding accordingly.”); Wolf et al., Managing Incidental Findings, supra note 
8, at 237 (“The cost of compensating the consultant for [incidental findings] 
verification and evaluation should be built into the research budget. . . . Agen-
cies funding research should support this expense as a cost of performing re-
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easy solution, making researchers bear more costs could have a 
significant impact on the research enterprise and future re-
search projects.  
First, given the complex issue of calculating the costs to re-
turn incidental findings, researchers will face a daunting chal-
lenge to predict the funding they will need to return results. 
The cost to return incidental findings is likely to vary substan-
tially depending on a number of factors, including the design of 
the research study.177 Ambiguity over what needs to be re-
turned and how these results should be returned adds to this 
complexity. This likely adds costs as researchers try to deter-
mine what they must do to be ethically and legally compliant.  
Assuming the current budget for medical research funding 
remains the same, as research projects require more funding, 
fewer projects will actually receive funding. Once again, society 
must face a trade-off between fewer research projects that re-
ceive more funding and return more incidental findings or more 
research projects that have less funding and return fewer find-
ings.  
Rising costs of medical research are especially alarming in 
light of recent budgetary concerns. The National Institutes of 
Health (NIH) funding ratio has been cut in half over the last 
decade.178 While NIH and other granting agencies face less 
funding and researchers face increased costs, the result could 
be fewer genetics and genomics research projects being funded 
and long-term problems, such as researchers leaving the field 
or researchers moving away from genetics and genomics re-
search.179  
 A recent study has found that Canadian participants would 
be willing to pay on average $445 to receive certain incidental 
findings from genomic sequencing.180 The study also found that 
only 66% of participants would choose to receive these re-
sults.181 While this may provide evidence that some costs may 
be shifted to the participants, the ethical or legal obligations of 
 
search ethically.”).  
 177. See Fernandez et al., supra note 91 (listing three broad categories that 
affect the complexity of returning results).  
 178. Szabo, supra note 20. 
 179. Id.; see also Pomeroy & Kandel, supra note 23. 
 180. Dean A. Regier et al., Societal Preferences for the Return of Incidental 
Findings from Clinical Genomic Sequencing: A Discrete-Choice Experiment, 
187 CAN. MED. ASSOC. J. 190, 195 (2015). These results were likely to have se-
vere health consequences, but there was recommended effective medical 
treatment. Id.  
 181. Id.  
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requiring participants to pay for receiving incidental findings is 
unclear.  
The threat of legal liability adds to genetics and genomics 
research concerns. Although no court has held a researcher lia-
ble for failure to return or improperly returning incidental find-
ings, ethical recommendations can begin to evolve into legal 
standards of care. Requiring researchers to foot the bill for the 
cost to return and to face potential liability can have negative 
consequences on the research enterprise.  
D. HOW LONG DOES THIS RESPONSIBILITY TO RETURN  
INCIDENTAL FINDINGS LAST? 
If researchers have to return incidental findings to re-
search participants, then researchers need to know how long 
they bear this responsibility. Jarvik and colleagues recommend 
that this responsibility last only during the period of funding to 
researchers.182 They go on to say, however, that researchers 
may offer disclosure after the funding period ends.183 Other 
commentators agree with Jarvik and her co-authors and argue 
that the responsibility to offer ends after the research project is 
over;184 however, some do not explicitly limit the responsibility. 
How long the responsibility lasts raises a question about 
the researchers’ responsibility to recontact participants after 
the research project ends. Many commentators argue that such 
a duty would extend researchers’ responsibilities beyond the 
responsibilities placed on clinicians. Clinicians are not required 
to monitor their patients’ conditions continuously, but rather 
they respond to specific symptoms and situations when their 
patients come in for an appointment.185 It is unusual for a clini-
cian to recontact a patient based on new research.186 So, to re-
quire a researcher to recontact would push the duties of a re-
searcher beyond the duties that exist in clinical practice.187 
Recontacting previous research participants can be costly 
and time-consuming.188 A 2011 study led by Kurt D. Christen-
sen and colleagues attempted to recontact 39 participants to 
disclose CDKN2A gene test results and implications for mela-
 
 182. Jarvik et al., supra note 18, at 823. 
 183. Id.  
 184. See, e.g., Fabsitz et al., supra note 147, at 577.  
 185. Clayton & McGuire, supra note 14, at 475. 
 186. Id.  
 187. Id. at 476.  
 188. See, e.g., Deborah Levenson, Legal, Ethical Issues Loom over Topic of 
Recontacting Patients, 167 AM. J. GENETICS vii, vii (2015).  
2016] A RESPONSIBLE DEFAULT 1199 
 
noma risk.189 Per recontact attempt, the preparation to disclose 
the results cost $611 and required 40 minutes.190 However, 
costs to recontact are likely to vary. In the 2011 study, the re-
searchers attempting to recontact participants had access to 
experts in clinical genetics, genetic counseling, and other 
health experts.191 This allowed the team to make specific rec-
ommendations for potential follow-up.192 Christensen and col-
leagues note that “[r]esearchers lacking the same access to in-
terdisciplinary expertise may need to seek institutional 
partners,”193 which will likely add to the cost of recontact.  
Issues of how long a researcher’s responsibility to return 
results lasts and researchers’ potential responsibilities to re-
contact participants raise cost and resource concerns. On one 
end of the spectrum, the researcher’s responsibility could cease 
with the research study. On the other end, researchers may 
have duties that extend beyond the funding period and beyond 
those of clinicians. The issue of how long this responsibility ex-
tends is important for the legal issues it implicates. As ethical 
recommendations are adopted and standards of care are creat-
ed, legal standards are likely to begin evolving. Eventually, the 
threat of liability and the costs of legal compliance may exceed 
the benefits or feasibility of performing genetics or genomics 
research, ethically and legally.  
E. WHAT ARE THE COSTS OF NOT RETURNING INCIDENTAL  
FINDINGS?  
While returning incidental findings is a costly endeavor, a 
researcher’s failure to return an incidental finding can also im-
pose costs on the health care system and the research enter-
prise. To illustrate these potential costs, one should return to 
the hypothetical in the introduction. If Sandy Cohen underwent 
genomic sequencing for research, but the researchers did not 
return her BRCA1 incidental finding, and Sandy discovers sev-
eral years later that she has breast cancer—what are the im-
plications for society and for the research enterprise? 
One cost to society could be increased costs on the health 
care system. It is possible that if participants are given inci-
dental findings then they could seek preventative treatment 
 
 189. Christensen et al., supra note 171.  
 190. Id. at 526–27.  
 191. Id. at 527.  
 192. Id. at 527–28. 
 193. Id. at 528.  
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that could avoid major costs down the road.194 Delaying treat-
ment can impose additional costs on the health care system due 
to additional testing; more drastic medical care, such as surger-
ies or operations that may have been preventable if the disease 
had been caught earlier; and increased hospital stays and 
treatment. These costs are very difficult to quantify, and it is 
not always clear that the incidental finding will provide an op-
portunity for preventative care or that a participant would un-
dergo preventative care, even if the care were available.  
Not only could not returning incidental findings lead to 
costs for society in general, but not returning findings can also 
lead to direct costs to the research enterprise. One such cost 
may be the loss of the public’s trust in the research enterprise. 
Loss of trust can lead to fewer research participants.195 Several 
studies have concluded that most participants want to know 
these research results196 and may feel some entitlement to re-
ceive these results.197 Thus, the failure to return incidental find-
ings can lead to bad publicity for the research enterprise. Bad 
publicity, loss of trust, and lack of reciprocity may have cost 
implications for the research enterprise and may threaten the 
sustainability of genomics and genetics research as fewer indi-
viduals decide to participate in these studies. Although these 
costs are nearly impossible to quantify, the cost of not return-
ing incidental findings should be considered as researchers de-
termine what incidental findings should be returned to partici-
pants.  
This Part has shown that offering to returning incidental 
 
 194. See, e.g., Jolie, supra note 6 (describing Angelina Jolie’s story of un-
dergoing a preventative double mastectomy after her doctors discovered she 
had a BRCA1 mutation).  
 195. Cf. Beskow et al., supra note 141, at 492 (arguing that for scientists 
who maintain genomic biobanks, “trust . . . is essential to their continued ex-
istence”).  
 196. See, e.g., Caroline Savage Bennette et al., Return of Incidental Find-
ings in Genomic Medicine: Measuring What Patients Value—Development of 
an Instrument to Measure Preferences for Information from Next-Generation 
Testing (IMPRINT), 15 GENETICS MED. 873, 873 (2013) (investigating partici-
pants’ preferences for incidental findings); Juli Murphy Bollinger et al., Public 
Preferences Regarding the Return of Individual Genetic Research Results: 
Findings from a Qualitative Focus Group Study, 14 GENETICS MED. 451, 452 
(2012) (finding that most participants wanted their individual research re-
sults). But see Clayton & McGuire, supra note 14, at 474 (“It is also difficult to 
assess participants’ general preferences regarding return of results when it is 
not clear what specific results might become available.”).  
 197. See Bollinger et al., supra note 196, at 453 (“For many, the desire . . . 
appeared to be related to a sense of ownership, i.e., that information about 
their genes belongs to them.”).  
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findings is costly on the research enterprise, but not offering to 
return these findings can also impose costs. Although many 
commentators cite costs of returning incidental findings as a 
major concern, these costs are not well understood and current 
data on the costs to offer incidental findings in genetics and ge-
nomics research is lacking. Until more data is available, how-
ever, genetics and genomics researchers find themselves in a 
difficult situation. With limited funding and scarce resources, 
genetics and genomics researchers need guidance to allocate 
resources efficiently while complying with their ethical and le-
gal obligations. Part III of this Note proposes a responsible de-
fault rule and much-needed guidance to assist genetics and ge-
nomics researchers in their decision to offer or not offer 
incidental findings to research participants.  
III.  DEFINING AN ETHICALLY, LEGALLY, AND FISCALLY 
RESPONSIBLE DEFAULT RULE   
Policymakers making ethical recommendations to medical 
researchers must consider the cost and legal implications of 
their recommendations. As analyzed above, the issue of return-
ing incidental findings to research participants is a complex 
and multi-faceted problem. Questions about what should be re-
turned, who should return results, who should pay for the re-
turning, and how long a duty extends require serious consider-
ation by policymakers. Any proposed recommendations for 
genetics and genomics researchers encompass ethical, legal, 
cost, and societal issues that require further research and eval-
uation. But, in the face of limited data and research on the cost 
of returning incidental findings to participants, policymakers 
need to give guidelines that allow researchers to fulfill the pur-
pose of their research without overburdening the research en-
terprise. Sections A through E will address the distinct ques-
tions presented above as to what incidental findings should be 
returned, who should return the findings, who should pay, how 
long a duty to return should last, and what are the costs of not 
returning. Section F will provide a default rule and explain how 
this default places minimal burdens on researchers and pro-
vides much needed guidance and security from the threat of fu-
ture legal liability.  
A. WHAT INCIDENTAL FINDINGS SHOULD BE OFFERED WILL  
DEPEND ON THE RESEARCH STUDY 
What results should be returned is a complex question that 
1202 MINNESOTA LAW REVIEW [100:1171 
 
encapsulates other complicated issues.198 Informed consent, an-
alytical verification of results, actionability of results, and the 
duty to search for incidental findings make it difficult for re-
searchers to know what results should be offered to partici-
pants and what the cost of offering and returning those results 
will be. In general, policymakers should keep in mind that the 
goal of medical research is to produce generalizable 
knowledge.199  
Federal regulations require researchers to acquire in-
formed consent.200 Although this is a costly process, it is re-
quired both ethically and legally.201 Researchers should prepare 
their study in a way to ensure adequate informed consent, 
while still keeping the cost of informed consent manageable. 
Researchers should address the possibility of incidental find-
ings with participants up front in order to prevent the cost of 
reconsent later. Informed consent may be costly, but because it 
is required, researchers must abide by the Common Rule while 
managing the costs of informed consent to avoid hobbling the 
research study budget.202 
Whether research results must be verified in a CLIA-
certified lab is also a complex issue facing researchers and one 
that requires more research.203 But, whether CLIA certification 
is required does not negate the need for researchers to confirm 
the analytical validity of their results. This confirmation is 
needed to prevent undue harm to participants from false posi-
tives or other inaccurate results.204 Like informed consent, ana-
lytical verification is not a cost that can be avoided but is ra-
ther a cost to be accounted for and managed.  
Another issue facing genetics and genomics researchers is 
the difficulty of predicting how many incidental findings they 
may uncover in their research and whether these results are 
actionable.205 While policymakers have published recommenda-
tions for what should be returned, issues surrounding 
actionability make these obligations less than clear. This ambi-
guity raises legal concerns as different standards of care can 
 
 198. See supra Part II.A.  
 199. See Ulrich, supra note 18, at 128.  
 200. Requirements for Informed Consent, 45 C.F.R. § 46.116 (2014). 
 201. See supra Part II.A.1.  
 202. See Clayton & McGuire, supra note 14, at 475.  
 203. See supra Part II.A.2.  
 204. Criteria for IRB Approval of Research, 45 C.F.R. § 46.111 (2014), re-
quires that researchers minimize potential risks to participants.  
 205. See supra Part II.A.3.  
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evolve from different definitions of “actionable.” Recognizing 
this danger, policymakers should leave it to researchers to de-
cide what is actionable as this definition varies by context and 
research studies. Researchers should define what is actionable 
for the study and explain this to participants in the informed 
consent process. As long as researchers define actionability for 
their particular study and provide this information to partici-
pants, researchers should not be subjected to legal liability 
down the road for not adopting a different definition of 
actionability. 
Finally, researchers should not have a duty to search or 
hunt for incidental findings. Such a duty would be overly bur-
densome and would push researchers’ duties beyond the duties 
of clinicians, which have historically been more expansive than 
the duties of researchers.206 An ethical duty to search for inci-
dental findings would likely evolve into a legal duty, which will 
put more strain on the research enterprise. The benefits of 
searching for incidental findings should outweigh the costs of 
searching. While it looks like current costs are prohibitive, 
more research would help researchers and policymakers under-
stand the implications of ethical recommendations to search. 
B. WHO SHOULD OFFER TO RETURN INCIDENTAL FINDINGS MAY  
VARY BY STUDY 
Who returns incidental findings to research participants is 
an important question that has potential legal ramifications as 
those who return the results may open themselves up to legal 
liability down the road if they fail to adequately return the in-
cidental findings.207 Unfortunately, given the variety of research 
study designs and researchers’ expertise and knowledge in ge-
netics and genomics, a one-size-fits-all approach is unlikely to 
be appropriate to resolve the question of who should return the 
results.  
Researchers are likely to be the most qualified to deter-
mine their own resources and abilities to return incidental find-
ings. Thus, researchers should address this issue prior to ap-
plying for funding. They should consider who can best bear the 
cost and responsibility of returning incidental findings while 
still providing participants with the information necessary to 
make informed choices about their health care. Whether the re-
searchers offer to return the results or additional personnel are 
 
 206. See Clayton & McGuire, supra note 14, at 475–76.  
 207. See supra Part II.B.  
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hired for the task, researchers must ensure that they are giving 
participants adequate information while still managing the 
costs of the research project.  
C. COSTS OF RETURNING INCIDENTAL FINDINGS ARE LIKELY TO  
FALL ONTO RESEARCHERS 
Who should pay is an interesting question, because unlike 
in the medical profession, where costs are usually shifted to in-
surance companies, the research enterprise cannot always turn 
to insurers to cover additional costs. Researchers usually bear 
the costs of returning incidental findings to participants, mean-
ing researchers either include the costs in their proposal for re-
search funding or find other means by which to pay. Also, the 
cost to offer and return incidental findings is extremely difficult 
to calculate and thus, it is difficult for researchers to predict 
what costs they will face. As highlighted above, assigning the 
costs to researchers and the research enterprise could have a 
detrimental effect on the research enterprise. When giving eth-
ical recommendations, policymakers need to remember that the 
costs to return incidental findings will likely be borne by re-
searchers.  
D. THE DUTY TO OFFER AND RETURN INCIDENTAL FINDINGS  
SHOULD BE LIMITED  
A duty to return incidental findings should not extend past 
the research period. Furthermore, researchers should not have 
a duty to recontact participants to offer incidental findings. Re-
searchers, however, should not be barred from recontacting pri-
or research participants and offering to return results. But, re-
searchers should be wary of doing so, as this could become the 
standard of care in the industry and could thus expose re-
searchers to liability. Recontacting prior participants poses its 
own costs and challenges, and these challenges vary by re-
search design and can be hard to predict.208 Thus, policymakers 
should be explicit in their recommendations that researchers do 
not have a duty to return findings beyond the research period 
and have no duty to recontact participants.  
E. THE COSTS OF NOT OFFERING AND RETURNING RESULTS  
MAY BE SIGNIFICANT 
The costs of not returning should be included in the deter-
mination of whether to return incidental findings. First, the re-
 
 208. See supra Part II.D.  
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searcher should look at what the potential is for an individual 
to use this information to prevent increased health care costs in 
the future.209 Furthermore, researchers should be cognizant of 
how not returning findings can potentially lead to bad publicity 
for the research enterprise.210 Bad publicity may result in re-
duced trust in the research enterprise and fewer individuals 
who are willing to participate in genetics and genomics re-
search. These costs will likely depend on the actionability and 
pathogenicity211 of the incidental finding and thus these factors 
should be taken into account.  
F. A RESPONSIBLE DEFAULT FOR GENETICS AND GENOMICS  
RESEARCHERS 
Several previous recommendations divide the decision to 
return into three bins: should return, may return, and should 
not return.212 While this approach helps to provide some guid-
ance to researchers, a default rule that recognizes and accounts 
for the cost implications of returning and not returning inci-
dental findings is needed. A default rule should ensure that re-
searchers satisfy their ethical responsibilities without imposing 
unnecessary threats of legal liability or overly burdening the 
research enterprise with unsustainable costs that will threaten 
the goal of genetics and genomics research—to “pursue general-
izable knowledge that will benefit society.”213  
This proposed default rule requires that researchers offer 
to return the incidental findings to the research participant. 
But if the researcher weighs the costs and benefits of returning 
the results with the costs and benefits of not returning the in-
cidental finding and concludes that the costs of returning the 
results outweighs the costs of not returning, then she should 
have no responsibility to offer the incidental finding to the par-
ticipant. 
 
 
 209. While this calculation is very similar to whether the incidental finding 
is actionable, this takes actionability and looks at it from the standpoint of so-
ciety as a whole and how the return of an incidental finding can reduce costs 
on society, not just the participant.  
 210. See supra Part II.E.  
 211. Pathogenicity is the ability to cause a disease.  
 212. See, e.g., Jonathan S. Berg et al., Deploying Whole Genome Sequencing 
in Clinical Practice and Public Health: Meeting the Challenge One Bin at a 
Time, 13 GENETICS MED. 499, 501 (2011); Fabsitz et al., supra note 147, at 
579.  
 213. Ulrich, supra note 18, at 128.  
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Figure 1. Decision to return scale: Weighing the costs and 
benefits to return or not return.  
 
Figure 1 shows the weighing of the costs and benefits of 
the decision to return or not return incidental findings to re-
search participants.214 This approach takes into account the 
ethical, legal, and cost implications of returning or not return-
ing incidental findings. Sometimes, the costs of returning due 
to lack of information about the actionability and the low bene-
fit of possible preventive care will tip the scale to not return. 
Other times, however, the incidental finding may be easily veri-
fied and not overly burdensome to return, and by not returning 
the results, the researcher risks high reputational costs to the 
research enterprise, increased loss of trust, and increased fu-
ture costs to the health care system. In these cases, the re-
searcher should offer to return the incidental findings to the 
participant.  
Weighing the costs and benefits on either side is not an 
easy task, but the researcher should merely have the burden of 
showing that her decision to return or not to return was rea-
sonable. The researcher should, however, bear the burden be-
cause she is best equipped to make a determination as to 
whether it is better to return or not to return. Given the cur-
rent legal system, researchers should not be surprised or over-
whelmed by this burden, as the legal system often places the 
 
 214. Note that not all of the costs and benefit considerations are included 
in Figure 1. Figure 1 serves as a visual representation of how the balancing 
should work. Furthermore, these costs and benefits are fluid calculations that 
will likely vary significantly depending on the study.  
Cost to 
Return
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to Return
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burden on the party that has the most information and has the 
best ability to make an informed decision.215  
This default rule not only provides much needed guidance 
to researchers, but it may also provide security from the threat 
of legal liability. If courts begin to allow negligence claims 
against researchers for failure to offer incidental findings, this 
default rule will provide strong evidence that the researcher 
was reasonable in her decision not to offer incidental findings. 
The default rule provides a process by which the researcher can 
show that she weighed the costs and benefits of returning and 
not returning incidental findings to research participants, and, 
thus, her decision not to return the findings was not based on a 
negligent act, but rather a well-informed, reasonably grounded 
basis.  
  CONCLUSION   
Returning incidental findings to research participants, like 
Sandy Cohen, continues to be a hotly contested issue. Although 
no federal or state laws currently regulate the disclosure of 
these findings, the threat of legal liability is growing as more 
lawsuits are being brought against researchers, and as ethical 
recommendations are published and begin to establish a stand-
ard of care. The cost implications of the legal liability and the 
ambiguity surrounding potential liability raise serious concerns 
for researchers and society as a whole as the goal of medical re-
search is to promote the benefit of society through the discovery 
of scientific, generalizable knowledge.  
Policymakers need to recognize the potential for legal lia-
bility and need to consider the purpose of genetics and ge-
nomics research and the costs imposed on researchers by re-
quiring disclosure of incidental findings. The cost of this duty is 
difficult to calculate and will likely vary substantially depend-
ing on the particular study. This Note illuminates the urgent 
need for more empirical research on the costs implicated by re-
turning incidental findings in genomics and genetics research. 
Furthermore, this Note provides an ethically, legally, and fis-
cally responsible default rule for the return of incidental find-
ings. The default rule places a minimal burden on researchers 
and also provides guidance and a sense of security from the 
 
 215. Cf. RESTATEMENT (THIRD) OF TORTS: APPORTIONMENT LIABILITY § 8 
(AM. LAW INST. 2000) (“Factors assigning percentages of responsibility . . . in-
clude (a) the nature of the person’s risk-creating conduct, including any 
awareness or indifference with respect to the risks created by the conduct 
. . . .”).  
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threat of future legal liability.  
 
